28.07.19|Adi Pick The merged company will focus on Therapix's technology and assets pertaining to clinical-stage pharmaceutical applications of cannabis, and will include Destiny's genomics-based cannabis breeding techniques and development capabilities
28.03.19|Lilach BaumerIn December, Israel-based Therapix scrapped a deal to be acquired by Canadian FSD Pharma for $48 million worth of FSD stock
12.12.18|Tzally Greenberg In October, FSD agreed to buy Therapix for $48 million in stock, but a Tuesday filing by Therapix revealed that the companies have returned to the negotiating table
28.11.18|Tzally GreenbergOn a visit to Israel, the co-chairman of the company said he believes cannabis research is going to come from Israel and Australia. He expects China to become a significant player in the cannabis market
More stories in CTech
